Olivia Brayer
Stock Analyst at Cantor Fitzgerald
(2.95)
# 1,356
Out of 5,182 analysts
110
Total ratings
51.52%
Success rate
7.07%
Average return
Main Sectors:
Stocks Rated by Olivia Brayer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GOSS Gossamer Bio | Downgrades: Neutral | n/a | $0.37 | - | 2 | Mar 23, 2026 | |
| CTMX CytomX Therapeutics | Maintains: Overweight | $6 → $10 | $4.56 | +119.30% | 2 | Feb 4, 2026 | |
| INSM Insmed | Maintains: Overweight | $216 → $230 | $162.43 | +41.60% | 1 | Dec 16, 2025 | |
| IKT Inhibikase Therapeutics | Initiates: Overweight | $4 | $1.80 | +122.22% | 1 | Dec 11, 2025 | |
| VNDA Vanda Pharmaceuticals | Maintains: Overweight | $13 → $11 | $7.00 | +57.14% | 2 | Oct 30, 2025 | |
| UTHR United Therapeutics | Maintains: Overweight | $405 → $525 | $564.81 | -7.05% | 2 | Sep 10, 2025 | |
| BMRN BioMarin Pharmaceutical | Reiterates: Overweight | $90 | $55.50 | +62.16% | 15 | Feb 20, 2025 | |
| VRTX Vertex Pharmaceuticals | Reiterates: Overweight | $480 | $438.71 | +9.41% | 22 | Feb 11, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Neutral | $50 → $55 | $59.60 | -7.72% | 9 | Feb 4, 2025 | |
| GILD Gilead Sciences | Reiterates: Neutral | $80 | $139.71 | -42.74% | 10 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $10.90 | - | 1 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $1,015 | $761.85 | +33.23% | 8 | Oct 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $405 | $347.94 | +16.40% | 2 | Oct 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $220 | $318.85 | -31.00% | 23 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $10 | $15.61 | -35.94% | 5 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $6.5 | $2.50 | +160.00% | 4 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $72 | $49.51 | +45.43% | 1 | Apr 13, 2023 |
Gossamer Bio
Mar 23, 2026
Downgrades: Neutral
Price Target: n/a
Current: $0.37
Upside: -
CytomX Therapeutics
Feb 4, 2026
Maintains: Overweight
Price Target: $6 → $10
Current: $4.56
Upside: +119.30%
Insmed
Dec 16, 2025
Maintains: Overweight
Price Target: $216 → $230
Current: $162.43
Upside: +41.60%
Inhibikase Therapeutics
Dec 11, 2025
Initiates: Overweight
Price Target: $4
Current: $1.80
Upside: +122.22%
Vanda Pharmaceuticals
Oct 30, 2025
Maintains: Overweight
Price Target: $13 → $11
Current: $7.00
Upside: +57.14%
United Therapeutics
Sep 10, 2025
Maintains: Overweight
Price Target: $405 → $525
Current: $564.81
Upside: -7.05%
BioMarin Pharmaceutical
Feb 20, 2025
Reiterates: Overweight
Price Target: $90
Current: $55.50
Upside: +62.16%
Vertex Pharmaceuticals
Feb 11, 2025
Reiterates: Overweight
Price Target: $480
Current: $438.71
Upside: +9.41%
Bristol-Myers Squibb Company
Feb 4, 2025
Maintains: Neutral
Price Target: $50 → $55
Current: $59.60
Upside: -7.72%
Gilead Sciences
Dec 11, 2024
Reiterates: Neutral
Price Target: $80
Current: $139.71
Upside: -42.74%
Nov 14, 2024
Reiterates: Neutral
Price Target: n/a
Current: $10.90
Upside: -
Oct 23, 2024
Reiterates: Neutral
Price Target: $1,015
Current: $761.85
Upside: +33.23%
Oct 22, 2024
Reiterates: Overweight
Price Target: $405
Current: $347.94
Upside: +16.40%
Oct 11, 2024
Reiterates: Neutral
Price Target: $220
Current: $318.85
Upside: -31.00%
Sep 16, 2024
Reiterates: Overweight
Price Target: $10
Current: $15.61
Upside: -35.94%
May 9, 2024
Reiterates: Overweight
Price Target: $6.5
Current: $2.50
Upside: +160.00%
Apr 13, 2023
Initiates: Overweight
Price Target: $72
Current: $49.51
Upside: +45.43%